Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study
ConclusionsIn Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation, rivaroxaban may be associated with a similar risk of major bleeding but a lower risk of thromboembolism compared with warfarin. The potential benefit of 10 mg of rivaroxaban in this population requires further investigation.
Source: PLoS One - Category: Biomedical Science Authors: Yi-Cheng Lin Source Type: research
More News: Atrial Fibrillation | Biomedical Science | Bleeding | Coumadin | Databases & Libraries | Gastroenterology | Health Insurance | Insurance | Ischemic Stroke | Stroke | Study | Taiwan Health | Thrombosis | Warfarin